REVIVEBIO 次世代益生菌衍生外泌體首度亮相
Taiwanese biotech firm REVIVEBIO Co is set to launch the first commercial application of its next-generation probiotics (NGPs)-derived exosome by end-October.
The start-up was founded in 2023 by prominent Taiwanese pharmaceutical company Microbio Group, with a focus on NGPs and supported by over 15 years of rigorous scientific research.
“Unlike conventional probiotics such as Lactobacillus and Bifidobacterium species, which offer broad gut health benefits, NGPs are typically derived from the human microbiota and designed for precision – addressing metabolic disorders, inflammatory diseases, neurodegenerative conditions, and other serious health challenges.
“Our proprietary strain Parabacteriod goldsteinii RV-01 (P.Goldsteinii RV-01) for nutraceutical application has already achieved GRAS self-affirmation through a third-party institute, and is currently undergoing
GRAS review by US FDA,” Snow Hsieh, Business Development Director at REVIVEBIO, told CosmeticsDesign-Asia.
According to Hsieh, there is currently only one commercially available strain (Akkermansia muciniphila) with FDA-approved GRAS status, and
P.Goldsteinii RV-01 is “on its way” to become the second.
The company will be showcasing its latest P.Goldsteinii RV-01-based innovation called NEXOSOME at in-cosmetics Asia in Bangkok, Thailand, this November.
By harnessing NGP, the cosmetic ingredient is said to contain extracellular vesicle (EV) concentration of more than 500 billion/ml,offering significant potential in skin rejuvenation and regeneration,boosting of cellular energy to restore skin health, and targeted immunomodulation….
新聞連結 – REVIVEBIO to debut next-generation probiotics-derived exosome and commercial application